Tin tức & Cập nhật

FLASH: Light-activated hypericin ointment gets high marks in early-stage mycosis fungoides

Photodynamic therapy using topically applied hypericin 0.25% is effective against early-stage patch and plaque lesions in patients with mycosis fungoides−cutaneous T-cell lymphoma, while having a favourable safety profile, as shown in the phase III FLASH trial.

Bone surgery at lower-volume hospitals does not compromise survival, readmission

Surgical treatment for metastatic disease of bone (MDB) at lower-volume hospitals is not associated with poorer survival or more readmissions, according to a study.

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

The addition of erlotinib to best supportive care (BSC) provided better survival benefit than BSC only in individuals with unresectable/metastatic gall bladder cancer (GBC) with poor performance status (PS), according to a phase II/III open-label study.

Online intervention shows promise in psych support for partners of cancer patients

PartnerCARE, an online intervention designed to address mental health needs of caregiving partners of cancer patients, appears to be feasible and acceptable, a recent study has found. PartnerCARE also appears to be effective, inducing substantial improvements in psychological distress and anxiety.

Many cancer patients cannot cope with depressive symptoms

A large proportion of cancer patients suffering from depressive symptoms cannot seem to effectively manage this burden on their own, particularly those who tend to avoid dealing with their own problems, reports a recent analysis.

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

New drug applications approved by US FDA as of 16 - 31 July 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.